The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections

dc.contributor.authorMohamed, Moubarak
dc.contributor.authorKeneth Iceland, Kasozi
dc.contributor.authorHelal F., Hetta
dc.contributor.authorHazem M., Shaheen
dc.contributor.authorAbdur, Rauf
dc.contributor.authorHayder M., Al-kuraishy
dc.contributor.authorSafaa, Qusti
dc.contributor.authorEida M., Alshammari
dc.contributor.authorEmmanuel Tiyo, Ayikobua
dc.contributor.authorFred, Ssempijja
dc.contributor.authorAdam Moyosore, Afodun
dc.contributor.authorRitah, Kenganzi
dc.contributor.authorIbe Michael, Usman
dc.contributor.authorJuma John, Ochieng
dc.contributor.authorLawrence Obado, Osuwat
dc.contributor.authorKevin, Matama
dc.contributor.authorAli I., Al-Gareeb
dc.contributor.authorEmmanuel, Kairania
dc.contributor.authorMonica, Musenero
dc.contributor.authorSusan, Christina Welburn
dc.contributor.authorGaber, El-Saber Batiha
dc.description.abstractNovel therapies for the treatment of COVID-19 are continuing to emerge as the SARS-Cov- 2 pandemic progresses. PCR remains the standard benchmark for initial diagnosis of COVID-19 infection, while advances in immunological profiling are guiding clinical treatment. The SARS- Cov-2 virus has undergone multiple mutations since its emergence in 2019, resulting in changes in virulence that have impacted on disease severity globally. The emergence of more virulent variants of SARS-Cov-2 remains challenging for effective disease control during this pandemic. Major variants identified to date include B.1.1.7, B.1.351; P.1; B.1.617.2; B.1.427; P.2; P.3; B.1.525; and C.37. Globally, large unvaccinated populations increase the risk of more and more variants arising. With successive waves of COVID-19 emerging, strategies that mitigate against community transmission need to be implemented, including increased vaccination coverage. For treatment, convalescent plasma therapy, successfully deployed during recent Ebola outbreaks and for H1N1 influenza, can increase survival rates and improve host responses to viral challenge. Convalescent plasma is rich with cytokines (IL-1β, IL-2, IL-6, IL-17, and IL-8), CCL2, and TNFα, neutralizing antibodies, and clotting factors essential for the management of SARS-CoV-2 infection. Clinical trials can inform and guide treatment policy, leading to mainstream adoption of convalescent therapy. This review examines the limited number of clinical trials published, to date that have deployed this therapy and explores clinical trials in progress for the treatment of COVID-19en_US
dc.description.sponsorshipKabale Universityen_US
dc.identifier.citationMoubarak, M.; Kasozi, K.I.; Hetta, H.F.; Shaheen, H.M.; Rauf, A.; Al-kuraishy, H.M.; Qusti, S.; Alshammari, E.M.; Ayikobua, E.T.; Ssempijja, F.; et al. The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections. Life 2021, 11, 734. 10.3390/life11080734en_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.subjectCOVID-19 therapyen_US
dc.subjectCOVID-19 vaccineen_US
dc.subjectCOVID-19 convalescent therapyen_US
dc.subjectSARS-CoV-2 infectionen_US
dc.subjecthuman antibodiesen_US
dc.subjectvariants of concernen_US
dc.titleThe Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infectionsen_US


Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
2.07 MB
Adobe Portable Document Format
The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
1.71 KB
Item-specific license agreed upon to submission